altRx review

altRx lists compounded semaglutide from $89 a month and tirzepatide from $149. Its homepage advertises no membership surcharge, no price hike and the same price at every prescribed dose. The terms describe a single bundled subscription price covering platform access, clinical services and eligible pharmacy fulfillment, rather than separate itemized services. That supports comparing the advertised bundle, but not assuming that every future offer or every patient’s eligibility is guaranteed. The recurring intervals are disclosed at checkout, so retain the actual quote and renewal date. The tirzepatide cost guide explains why an introductory display, dose inclusion and billing interval all need to be clear.

Brand Ozempic, Wegovy and Zepbound appear on separate product pages with their own monthly headlines. Those offers should be evaluated separately from the low compounded-drug entry price, including exact presentation, quantity, membership services, eligibility and pharmacy route. A public monthly headline is not a substitute for a complete product-specific checkout quote. The Wegovy cost guide compares manufacturer self-pay and coverage conditions without assuming altRx supplies every branded form or that a compounded offer is an approved equivalent. Likewise, the compounded product pages’ trial-like weight-loss language cannot establish how this particular pharmacy preparation performs. The site’s footer says its member outcomes are self-reported rather than clinical-trial or peer-reviewed findings; those are a different kind of evidence.

The public care disclosures name OpenLoop Healthcare Partners, PC and affiliated independent practices for clinical assessment and prescribing. A consultation may be live video or asynchronous review depending on the provider and state requirements; the initial assessment alone does not create a provider-patient relationship or guarantee a prescription. The FAQ names RedRock, Health Warehouse, Precision Medicine and Triad Rx as pharmacy partners and describes the network as state-licensed 503A pharmacies. Treat that as the provider’s disclosed network, not independent confirmation of every current license or your dispensing assignment. Ask for the exact location and clinician assigned to you, since a company name can cover more than one license or facility. The membership is advertised in all 50 states with provider and prescribing availability qualified by state. This does not mean every product is available to every applicant.

The cancellation documents disagree: the refund policy requires requests at least 72 hours before billing, while the general terms describe 48 hours before monthly processing. Ask which applies to the specific subscription and obtain confirmation before the earlier published deadline rather than rely on a last-minute request. The refund policy makes payment final even if an intake is never completed, and treats a multi-month bundle as one nonrefundable purchase rather than refundable unused months. Its medical-disqualification exception returns only an unused portion after deducting consultations, review, prescriptions, pharmacy or laboratory services already provided or committed. It is not a guaranteed full refund for being denied a prescription. Damaged or incorrect items have a replacement procedure, not an ordinary cash-refund promise. Canceling stops future renewal; it does not automatically undo a paid commitment.

The semaglutide page also gives a 56-day room-temperature-after-opening statement without establishing stability data for the actual compounded preparation. FDA’s current guidance generally recommends discarding compounded multi-dose sterile vials within 28 days after first use, even when a compounder’s instructions allow longer. Do not transfer an approved brand’s storage limit to a different compounded vial; confirm the exact pharmacy label and resolve this discrepancy with the pharmacist. The compounded semaglutide storage guide covers that distinction. Finally, the terms identify OpenLoop Health as platform operator, the privacy statement uses a different company name and contact details, and the FDA correspondence names another legal entity. These documents do not establish every corporate relationship; request the contracting party rather than infer it from a logo. FDA’s letter concerns compounder presentation and claims of clinically proven compounded drugs, not proof of an independently verified product or regulatory closure.